152 related articles for article (PubMed ID: 35430566)
1. SLFN12 Over-expression Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy Drugs and Radiotherapy.
Raafat Elsayed AA; Al-Marsoummi S; Vomhof-Dekrey EE; Basson MD
Cancer Genomics Proteomics; 2022; 19(3):328-338. PubMed ID: 35430566
[TBL] [Abstract][Full Text] [Related]
2. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.
Al-Marsoummi S; Vomhof-DeKrey E; Basson MD
Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790
[TBL] [Abstract][Full Text] [Related]
3. A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.
Dinkelborg PH; Wang M; Gheorghiu L; Gurski JM; Hong TS; Benes CH; Juric D; Jimenez RB; Borgmann K; Willers H
Breast Cancer Res Treat; 2019 Apr; 174(3):605-613. PubMed ID: 30607635
[TBL] [Abstract][Full Text] [Related]
4. The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers.
Moens S; Zhao P; Baietti MF; Marinelli O; Van Haver D; Impens F; Floris G; Marangoni E; Neven P; Annibali D; Sablina AA; Amant F
Sci Rep; 2021 Feb; 11(1):3176. PubMed ID: 33542435
[TBL] [Abstract][Full Text] [Related]
5. The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy.
Zhou ZR; Yang ZZ; Wang SJ; Zhang L; Luo JR; Feng Y; Yu XL; Chen XX; Guo XM
Acta Pharmacol Sin; 2017 Apr; 38(4):513-523. PubMed ID: 28042876
[TBL] [Abstract][Full Text] [Related]
6. Schlafen Family Intra-Regulation by IFN-α2 in Triple-Negative Breast Cancer.
Brown SR; Vomhof-DeKrey EE; Al-Marsoummi S; Brown ND; Hermanson K; Basson MD
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067362
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
8. One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin.
Zhu H; Rao Z; Yuan S; You J; Hong C; He Q; Yang B; Du C; Cao J
Eur J Pharmacol; 2021 Oct; 908():174366. PubMed ID: 34314706
[TBL] [Abstract][Full Text] [Related]
9. Schlafen 12 Slows TNBC Tumor Growth, Induces Luminal Markers, and Predicts Favorable Survival.
Singhal SK; Al-Marsoummi S; Vomhof-DeKrey EE; Lauckner B; Beyer T; Basson MD
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672349
[TBL] [Abstract][Full Text] [Related]
10. Chk1 as a new therapeutic target in triple-negative breast cancer.
Albiges L; Goubar A; Scott V; Vicier C; Lefèbvre C; Alsafadi S; Commo F; Saghatchian M; Lazar V; Dessen P; Delaloge S; André F; Quidville V
Breast; 2014 Jun; 23(3):250-8. PubMed ID: 24636978
[TBL] [Abstract][Full Text] [Related]
11. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
[TBL] [Abstract][Full Text] [Related]
12. Curcumin sensitizes carboplatin treatment in triple negative breast cancer through reactive oxygen species induced DNA repair pathway.
Wang G; Duan P; Wei Z; Liu F
Mol Biol Rep; 2022 Apr; 49(4):3259-3270. PubMed ID: 35076853
[TBL] [Abstract][Full Text] [Related]
13. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
14. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation.
Choi C; Cho WK; Park S; Shin SW; Park W; Kim H; Choi DH
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294924
[TBL] [Abstract][Full Text] [Related]
16. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
Tu X; Kahila MM; Zhou Q; Yu J; Kalari KR; Wang L; Harmsen WS; Yuan J; Boughey JC; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
[TBL] [Abstract][Full Text] [Related]
19. Anticancer mechanism of 7-α-hydroxyfrullanolide on microtubules and computational prediction of its target binding in triple-negative breast cancer cells.
Chimplee S; Smythe C; Tipmanee V; Sukrong S; Kanokwiroon K
PeerJ; 2022; 10():e13508. PubMed ID: 35651747
[TBL] [Abstract][Full Text] [Related]
20. Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
Min DJ; He S; Green JE
Anticancer Res; 2016 Jun; 36(6):2649-57. PubMed ID: 27272773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
